Home / Stocks / Take Limited
TAKE

Take Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹13.04

Change

+0.61 (4.91%)

Open

₹12.64

Prev. Close

₹12.43

Day High

₹13.05

Day Low

₹12.2

Volume Analysis

Traded

1,173,154

Delivered

976,631

Delivery %

83.25%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Promoter holding is falling
  • •Below-average fundamentals quality score (39/100)
  • •Low operating margin (0.3%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹14.17 ₹13.61 ₹13.32 ₹12.76 ₹12.47 ₹11.91 ₹11.62
Fibonacci ₹13.61 ₹13.29 ₹13.08 ₹12.76 ₹12.44 ₹12.23 ₹11.91
Camarilla ₹13.27 ₹13.2 ₹13.12 ₹12.76 ₹12.96 ₹12.88 ₹12.81

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-67.67%

1 Week

+3.0%

1 Month

+14.69%

3 Months

-37.4%

6 Months

-55.34%

1 Year

-56.11%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹6.17

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.57%

Net margin 7.89% × asset turnover 1.35x × equity multiplier 1.18x

Company Overview

Sector

Healthcare

Market Cap

₹192 Cr

P/E (TTM)

22.0

ROE

16.5%

Book Value

₹2.32

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Take Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 39/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (39/100).

TopFund Score — Fundamentals Quality

39/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

40

Cash Flow

33

Corporate Governance

10

Momentum

8

Institutional Ownership

30

Business Quality

56

Risk & Volatility

33

Liquidity

52

From Screener.in

  • +Company is almost debt free.
  • −Stock is trading at 5.61 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -41.2% over past five years.
  • −Tax rate seems low

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

TAKE Limited reports H1 FY27 income of ₹615.54 million, PAT ₹32.75 million; launches TAKE.Health and ₹50 million innovation fund.

TAKE Limited filed Regulation 74(5) certificate for quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 0 0 0 0 0 0 0 0 0 0 54 30 29
Expenses + 2 2 16 2 1 3 1 0 0 0 55 31 28
Operating Profit -1 -2 -16 -2 -1 -3 -1 0 0 0 -1 0 2
OPM % -2,900.0% — — — — — — — — — -1.51% -0.89% 6.02%
Other Income + 0 4 -94 -1 0 51 -3 0 7 1 5 1 0
Interest 1 1 1 0 1 1 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit before tax -2 1 -110 -4 -2 48 -5 -1 6 1 4 1 2
Tax % -18.42% 248.61% 0.55% 1.63% -3.66% 0.0% 0.0% 0.0% 2.48% 0.0% 0.0% 0.0% 0.0%
Net Profit + -2 -2 -111 -4 -2 48 -5 -1 6 1 4 1 2
EPS in Rs 0 0 -7 0 0 3 0 0 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -100 -100 -100 -100 -100 — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 730 1,030 1,345 1,587 2,039 2,213 774 655 189 4 0 54 114
Expenses + 581 817 1,082 1,281 1,655 2,044 847 648 208 24 7 56 114
Operating Profit 149 213 262 307 384 169 -73 7 -19 -20 -7 -2 0
OPM % 20.0% 21.0% 20.0% 19.0% 19.0% 8.0% -9.0% 1.1% -10.0% -569.0% — -3.5% 0.3%
Other Income + 8 21 13 6 11 26 -211 -677 -56 -92 47 13 8
Interest 13 15 23 21 25 41 37 29 7 2 2 0 0
Depreciation 60 74 87 104 154 167 115 80 17 1 0 0 0
Profit before tax 85 145 165 188 216 -13 -437 -779 -99 -116 37 11 9
Tax % 6.0% 14.0% 11.0% 15.0% 17.0% -15.0% 3.0% 0.0% 2.0% 3.0% 0.0% 1.0% —
Net Profit + 80 125 146 160 178 -11 -450 -782 -100 -120 37 11 9
EPS in Rs 6 10 11 11 12 -1 -31 -53 -7 -8 3 1 1
Dividend Payout % 17.0% 10.0% 9.0% 15.0% 8.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -10 41 31 18 28 9 -65 -15 -71 -98 -100 — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 512 619 898 1,314 1,504 1,561 1,110 166 94 -24 6 16 19
Borrowings + 209 336 237 323 474 553 514 59 46 37 0 0 0
Other Liabilities + 189 246 221 189 339 336 187 984 69 60 16 5 6
Total Liabilities 922 1,214 1,369 1,840 2,331 2,465 1,826 1,223 224 88 36 36 40
Fixed Assets + 359 543 554 589 1,091 1,234 934 101 73 30 0 0 0
CWIP 17 3 21 42 41 1 0 3 11 0 0 0 0
Investments 6 21 10 59 10 18 7 0 0 0 0 0 0
Other Assets + 541 647 785 1,150 1,188 1,213 885 1,119 140 58 36 36 40
Total Assets 922 1,214 1,369 1,840 2,331 2,465 1,826 1,223 224 88 36 36 40
Equity Capital 12 12 13 15 15 15 15 15 15 15 15 15 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 74 151 56 121 104 211 135 30 20 9 -16 -4
Cash from Investing Activity + -14 -292 -130 -179 -474 -233 -57 15 -3 -7 22 2
Cash from Financing Activity + -11 111 56 302 100 21 -84 -55 -36 -12 -3 -1
Net Cash Flow 49 -30 -18 243 -270 -2 -6 -10 -18 -10 3 -3
Free Cash Flow 46 35 -30 39 -23 54 133 -2 -12 2 -16 -4
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 52 76 26 44 30 156 -212 704 -114 -43 217 208

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 53.41% → 0.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 46.59% 46.56% 46.58% 46.58% 46.59% 46.58% 46.65% 94.81% 99.44% 99.73% 99.8% 99.79%
Promoters 53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.34% 5.19% 0.0% 0.0% 0.0% 0.0%
FII 0.0% 0.02% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.56% 0.28% 0.2% 0.21%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.01% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Take Limited (this stock) 192 22.0 5.6 16.5%
Nectar Lifesciences Ltd. 193 — 0.34 -31.3%
Bilcare Ltd. 202 5.55 1.13 1.39%
Brooks Lab Limited 203 58.7 1.08 22.0%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Natural Capsules Limited 144 — 0.66 -9.45%

Which Mutual Funds Hold Take Limited?

Frequently Asked Questions about Take Limited

Community Sentiment

What are other investors saying about Take Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.